跳到正文
原文
Nature 健康护理主题·· 11 天前AI 评分35

EBMT 细胞治疗标准化委员会关于 CAR T 细胞冷冻保存的方法学建议

Cryopreservation of academic CAR T-cell products: methodological recommendations from the EBMT practice harmonisation and guidelines committee

AI 导读

EBMT 细胞治疗标准化委员会发布了关于学术 CAR T 细胞产品的冷冻保存方法学建议。该指南总结了当前细胞和基因治疗的挑战,并提供了冷冻保存技术在 CAR T 细胞生产、运输和储存中的应用建议。

正文

Data availability

All data generated or analyzed during this study are included in this published article.

References

  1. Sanchez-Guijo F, Vives J, Ruggeri A, Chabannon C, Corbacioglu S, Dolstra H, et al. Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT). Cytotherapy. 2024;26:681–5. https://doi.org/10.1016/j.jcyt.2024.02.007.

    Article  CAS  PubMed  Google Scholar 

  2. Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D. Systematic review on CAR-T cell clinical trials up to 2022: academic center input. Cancers. 2023;15; https://doi.org/10.3390/cancers15041003.

  3. Vucinic V, Quaiser A, Luckemeier P, Fricke S, Platzbecker U, Koehl U. Production and application of CAR T cells: current and future role of Europe. Front Med. 2021;8:713401. https://doi.org/10.3389/fmed.2021.713401.

    Article  Google Scholar 

  4. Aleksandrova K, Leise J, Priesner C, Aktas M, Apel M, Assenmacher M, et al. Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma. Front Immunol. 2024;15:1328368. https://doi.org/10.3389/fimmu.2024.1328368.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Jandova M, Stacey GN, Lanska M, Gregor I, Rozsivalova P, Bekova L, et al. The role of cryopreservation techniques in manufacturing, transport, and storage of Car-T therapy products. Cryo Lett. 2023;44:123–33.

    Article  Google Scholar 

  6. Worel N, Ljungman P, Verheggen ICM, Hoogenboom JD, Knelange NS, Eikema DJ, et al. Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP). Bone Marrow Transpl. 2023;58:1348–56. https://doi.org/10.1038/s41409-023-02099-w.

    Article  CAS  Google Scholar 

  7. Novitzky-Basso I, Fu E, Alvarez M, Chiarello C, Najemeldin A, Kawari M et al. Don t fly and freeze: impact of ex vivo time, cell density and cryopreservation on allogeneic stem cell grafts. Cytotherapy. 2025; https://doi.org/10.1016/j.jcyt.2025.09.002.

  8. Nijssen K, Westinga K, Stuut A, Janssen A, van Rhenen A, van der Wagen L, et al. Graft engineering: how long can you wait, how low can you go, and pandemic readiness. Bone Marrow Transpl. 2023;58:820–2. https://doi.org/10.1038/s41409-023-01976-8.

    Article  Google Scholar 

  9. Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P, et al. Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics. Mol Ther. 2019;27:1275–85. https://doi.org/10.1016/j.ymthe.2019.05.015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Jiang G, Neuber B, Huckelhoven-Krauss A, Hopken UE, Ding Y, Sedloev D et al. In vitro functionality and endurance of GMP-compliant point-of-care BCMA.CAR-T cells at different timepoints of cryopreservation. Int J Mol Sci. 2024;25; https://doi.org/10.3390/ijms25031394.

  11. Brezinger-Dayan K, Itzhaki O, Melnichenko J, Kubi A, Zeltzer LA, Jacoby E, et al. Impact of cryopreservation on CAR T production and clinical response. Front Oncol. 2022;12:1024362. https://doi.org/10.3389/fonc.2022.1024362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Yakoub-Agha I, Greco R, Onida F, de la Camara R, Ciceri F, Corbacioglu S, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transpl. 2023;58:696–700. https://doi.org/10.1038/s41409-023-01958-w.

    Article  Google Scholar 

  13. Fisher V, Khuu H, David-Ocampo V, Byrne K, Pavletic S, Bishop M, et al. Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation. Transfusion. 2014;54:1088–92. https://doi.org/10.1111/trf.12428.

    Article  CAS  PubMed  Google Scholar 

  14. Li R, Johnson R, Yu G, McKenna DH, Hubel A. Preservation of cell-based immunotherapies for clinical trials. Cytotherapy. 2019;21:943–57. https://doi.org/10.1016/j.jcyt.2019.07.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

A great thanks to all colleagues across EBMT centers who responded to the survey presented in this work. List provided in the Supplemental document.

Funding

The European Group for Blood and Bone Marrow transplantation (EBMT) is a non-for-profit medical and scientific organisation. The EBMT performed administrative and legal management, as well as funding acquisition. No pharmaceutical company and no other funding source were involved in any way or had a role in the study design, data collection, data analysis, data interpretation, or writing of the report. No medical writer or editor was involved.

Author information

Author notes

  1. These authors contributed equally: Halvard Bonig, Boris Calmels, Camille Giverne, Ulrike Köhl, Jürgen Kuball, Chantal Lechanteur, Trudy Straetemans, Nina Worel, Ibrahim Yakoub-Agha.

Authors and Affiliations

  1. Institute for Transfusion Medicine and Immunohematology, Goethe University and German Red Cross Blood Service BaWueHe, Frankfurt, Germany

    Halvard Bonig

  2. Centre de Thérapie Cellulaire, Institut Paoli-Calmettes, INSERM CIC Biothérapie BT-510, Marseille, France

    Boris Calmels

  3. CHU de Rouen, laboratoire d’Immunologie et Biothérapies, Université de Rouen Normandie, INSERM, UMR 1234, Rouen, France

    Camille Giverne

  4. Fraunhofer Institute of Cell therapy and Immunology; Institute of Clinical Immunology, University and University hospital, Leipzig, Germany

    Ulrike Köhl

  5. Center for Translational Immunology, & Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands

    Jürgen Kuball & Trudy Straetemans

  6. Laboratoire de thérapie cellulaire et génique (LTCG), Hématologie Clinique, CHU de Liège, Liège, Belgique

    Chantal Lechanteur

  7. Hematology and BMT Unit, ASST Fatebenefratelli-Sacco, Dept. of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

    Francesco Onida

  8. Co chair of the EBMT Practice Harmonisation Committee, Barcelona, Spain

    Francesco Onida & Annalisa Ruggeri

  9. EBMT Chief Medical Officer, Barcelona, Spain

    Isabel Sánchez-Ortega

  10. Secretary of the EBMT Practice Harmonisation and Guidelines Committee, Barcelona, Spain

    Isabel Sánchez-Ortega

  11. Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy

    Annalisa Ruggeri

  12. Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria

    Nina Worel

  13. CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France

    Ibrahim Yakoub-Agha

  14. Chair of the EBMT Practice Harmonisation and Guidelines Committee, Barcelona, Spain

    Ibrahim Yakoub-Agha

Authors

  1. Halvard Bonig
  2. Boris Calmels
  3. Camille Giverne
  4. Ulrike Köhl
  5. Jürgen Kuball
  6. Chantal Lechanteur
  7. Francesco Onida
  8. Isabel Sánchez-Ortega
  9. Annalisa Ruggeri
  10. Trudy Straetemans
  11. Nina Worel
  12. Ibrahim Yakoub-Agha

Contributions

UK, AR, FO, ISO, JK, and IY-A conceived and designed the manuscript topics and developed the survey questions. All co-authors contributed to the literature review, data interpretation, formulation of recommendations, and preparation of the figures and tables. In addition, all co-authors played an important role in drafting the recommendations, revising the manuscript, approving the final version, and agreeing to be accountable for all aspects of the work to ensure that any issues related to accuracy or integrity are properly investigated and resolved. All co-authors contributed equally to this work and are therefore listed in alphabetical order.

Corresponding author

Correspondence to Ibrahim Yakoub-Agha.

Ethics declarations

Competing interests

HB has received research support from Bayer, Chugai, Erydel, Fresenius, Miltenyi, Sandoz-Hexal, Terumo BCT, honoraria/speakers‘ fees from BMS/Celgene, Fresenius, Kiadis, Miltenyi, Novartis, Terumo BCT, has served on consultancy/advisory boards of Apriligen, Arensia, Boehringer Ingelheim Vetmed, BMS/Celgene, Byondis, Editas, medac, NMDP, Novartis, Provirex, Sandoz-Hexal, receives royalties/licensing fees: medac, owns stock in Healthineers, is the founder and owner of S.P.I. GMP-Consultants, LLC. BC declares no COI related to this work. CG declares no COI related to this work. UK received consultant and/or speaker fees from AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna, CGT manufacturing: Miltenyi Biotec and Novartis Pharma GmbH, Bristol-Myers Squibb GmbH & Co. JK Cofounder and shareholder of Gadeta Founders B.V., inventor on patents related to γδTCR/ligand and genetic engineering, and has received research funding from Novartis, Miltenyi Biotech, and Gadeta. For full disclosure, see: https://researchinformation.umcutrecht.nl/en/persons/jurgen-kuball. CL declares no COI related to this work. FO Honoraria: Takeda, MEDAC Pharma, Kyowa Kirin; Travel support: Takeda, Jazz Pharma, Kyowa Kirin. IOS declares no COI related to this work. AR received honoraria from Kite/Gilead. TS has received speakers fee from Miltenyi Biotec. NW has received research funding from Sanofi Genzyme and Therakos and speaker fees from BMS Celgene, Johnson & Johnson, Kite Gilead, Miltenyi Biotec, and Therakos. IY-A received honoraria from Kite/Gilead, BMS, Novartis.

Declaration of Generative AI Use

This manuscript was written by human authors. During the preparation of this work, the authors used ChatGPT™ to enhance the clarity, conciseness, and grammatical accuracy of the text. Following this assistance, all content was carefully reviewed and edited by the authors, who take full responsibility for the final ver ion of the manuscript.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bonig, H., Calmels, B., Giverne, C. et al. Cryopreservation of academic CAR T-cell products: methodological recommendations from the EBMT practice harmonisation and guidelines committee. Bone Marrow Transplant (2026). https://doi.org/10.1038/s41409-026-03020-x

Download citation

  • Received: 09 December 2025

  • Revised: 23 June 2026

  • Accepted: 12 August 2026

  • Published: 09 November 2026

  • Version of record: 09 November 2026

  • DOI: https://doi.org/10.1038/s41409-026-03020-x

来源:Nature 健康护理主题 · nature.com